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Abstract
Chronic hepatitis B (CHB) is a major global health 
problem affecting an estimated 350 million people 
with more than 786000 individuals dying annually due 
to complications, such as cirrhosis, liver failure and 
hepatocellular carcinoma (HCC). Liver transplantation 
(LT) is considered gold standard for treatment of 
hepatitis B virus (HBV)-related liver failure and HCC. 
However, post-transplant viral reactivation can be 
detrimental to allograft function, leading to poor 
survival. Prophylaxis with high-dose hepatitis B 
immunoglobulin (HBIG) and anti-viral drugs have 
achieved remarkable progress in LT by suppressing 
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viral replication and improving long-term survival. 
The combination of lamivudine (LAM) plus HBIG has 
been for many years the most widely used. However, 
life-long HBIG use is both cumbersome and costly, 
whereas long-term use of LAM results in resistant 
virus. Recently, in an effort to develop HBIG-free 
protocols, high potency nucleos(t)ide analogues, 
such as Entecavir or Tenofovir, have been tried either 
as monotherapy or in combination with low-dose 
HBIG with excellent results. Current focus is on novel 
antiviral targets, especially for covalently closed circular 
DNA (cccDNA), in an effort to eradicate HBV infection 
instead of viral suppression. However, there are several 
other molecular mechanisms through which HBV may 
reactivate and need equal attention. The purpose of this 
review is to address post-LT HBV reactivation, its risk 
factors, underlying molecular mechanisms, and recent 
advancements and future of anti-viral therapy.
Key words: Hepatitis B virus; Liver transplantation; 
Reactivation; Hepatitis B immunoglobulin; Recurrence; 
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Core tip: Aim of this review is to summarize the current 
concepts and management of hepatitis B after liver 
transplantation (LT). There are no clear guidelines 
regarding hepatitis B therapy after transplantation. 
Hepatitis B immunoglobulin (HBIG) is expensive and 
cumbersome to administer and there is no definite time 
point for discontinuation of HBIG after LT. Here we 
summarize the indications and duration of hepatitis B 
immunoglobulin and nucleoside analogs. This review 
also addresses key molecular mechanisms and the 
risk factors which are associated with hepatitis B virus 
reactivation post LT. This review provides up-to-date 
information not only for the liver transplant specialists 
but also for the virologists and scientists working in this 
field.
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INTRODUCTION
Chronic hepatitis B (CHB) caused by hepatitis B virus 
(HBV) infection remains a major global health problem 
affecting an estimated 350 million people worldwide 
with more than 786000 individuals dying annually 
due to complications of CHB, including cirrhosis and 
liver cancer. CHB is the leading cause of hepatocellular 
carcinoma (HCC) accounting for at least 50% of 
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newly diagnosed cases[1]. Furthermore, HCC is the 
third leading cause of cancer-related mortality in the 
world[2] with a dismal 5 year survival and the fastest 
growing rate of cancer death in North America[3]. Liver 
transplantation (LT) is the most effective treatment in 
patients with CHB-related liver failure, cirrhosis and 
HCC. However, HBV reactivation following LT emerges 
as a major clinical challenge[4]. 
Over the past decade, a substantial advancement 
has been made in the treatment of CHB, and to date 
several potent antiviral medications are available for the 
treatment of HBV infection, mainly gaining long-term 
viral suppression[5,6]. However, despite of having strong 
suppressive antiviral therapy for chronically HBV-infected 
patients, some patients still develop HCC possibly due 
to the presence of minimal residual viremia (MRV) and 
irreversible HBV DNA integration into liver genome. MRV 
is a consequence of persistent, low-level virus replication 
in the liver and at the extrahepatic sites, particularly in 
peripheral blood mononuclear cells (PBMC), coinciding 
with circulation of virus traces[7-10]. Despite long-term 
antiviral treatment with suppression of viral DNA, MRV 
commonly persist[7,11]. One of the major sources of 
MRV is supercoiled HBV covalently closed circular DNA 
(cccDNA) and its persistence is mainly responsible 
for recurrent HBV infection post-LT[12,13]. Prior to 
introduction of hepatitis B immunoglobulin (HBIG) in 
1990s, HBV recurrence in LT was as high as 75% to 
89% of patients with 3-year survival rate in 54%[14,15]. 
The introduction of viral suppression strategy using 
combination of HBIG and more potent nucleos(t)ide 
analogs (NAs) has significantly decreased the HBV 
recurrence in vast majority of these patients improving 
their long-term survival[16]. However, this strategy does 
not completely eradicate HBV and, therefore, does not 
protect against future recurrence of symptomatic HBV 
infection. It also requires monitoring of LT patients for 
life, thus significantly increasing the economic burden 
and manpower engagement.
Evaluating the risk of HBV recurrence is crucial in 
devising effective strategy against post-LT reactivation. 
The factors associated with high rates of HBV 
reactivation are high viral load prior to the transplant, 
HBV e antigen (HBeAg) reactivity, co-infection with 
human immunodeficiency virus type 1 (HIV), non-
compliance with drug therapy, HCC at the time of LT, 
and anti-viral drug resistance. On the other hand, low 
viral load, anti-HBe positivity and anti-HBs presence are 
factors with lower risk of HBV reactivation[15,17-21].
MOLECULAR MECHANISMS OF 
HEPATITIS B REACTIVATION IN LIVER 
TREANSPLANTATION
cccDNA and its role in HBV reactivation 
Although HBV is a DNA virus, it replicates by reverse 
transcription intermediate[22]. Establishment of cccDNA 
is crucial in the HBV life cycle. This nuclear cccDNA 
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minichromosomal acts as the powerhouse of HBV 
transcriptional machinery and constitutes a molecular 
basis for virus reactivation[12]. HBV cccDNA chronically 
exists throughout the natural history of HBV infection[23] 
and it is not yet possible to eradicate this HBV molecule 
even with current potent anti-viral therapies, such 
as Entecavir (ETV) or Tenofovir disoproxil fumarate 
(TDF)[24]. A recent study by Papatheodoritis et al[25] 
showed that despite of the anti-HBV therapy, HCC 
develops in the context of the cccDNA presence and, 
thus, MRV and reactivation cannot be ruled out. 
When recipients receive transplantation with liver 
from donors with previous history of HBV infection, but 
with negative serum HBsAg and HBV DNA, intrahepatic 
cccDNA could still be detected after LT[4,26]. Notably, 
detection of anti-HBc alone in the absence of HBsAg and 
HBV DNA in a donor should be treated as an indicator 
of occult infection and a low-level virus replication in 
the liver, which could be reactivated post-LT[18,27,28]. On 
the other hand, patients with undetectable HBV viremia 
at LT and no evidence of cccDNA and intrahepatic 
HBV DNA on repeat examinations -may be safely 
withdrawn from long-term prophylaxis[29]. However, safe 
withdrawal also depends on the level of the sensitivity of 
the assays used for detecting HBV viremia, HBV cccDNA 
in the liver and the existence of HBV replication at the 
extrahepatic sites [e.g., peripheral blood mononuclear 
cells (PBMC)], which in occult cases may be missed 
even using ultrasensitive tests.
Genotype-specific recurrence of HBV
Ten different HBV genotypes have been identified 
which are scattered in an ethno-geographically specific 
manner. Ample of evidence suggested the role of 
HBV genotypes in disease progression, mode of 
transmission, disease severity, HCC risk, and response 
to therapy[30]. Compared to genotype D, HBV genotype 
A responds well to the interferon therapy[31]. Numerous 
reports across the globe documented association of HBV 
genotype B and C with severe liver disease including 
development of HCC[32], while HBV genotype C has 
higher risk for mother to child transmission[33]. Since 
virus evolves within the host, study of HBV genotype 
is important prior to LT, especially in genotypes, which 
are associated with the occult HBV infection[34,35]. A 
study by Devarbhavi et al[34] demonstrated that patients 
with HBV genotype D have the highest risk of HBV 
recurrence and mortality compared to genotype A. In 
our recent study, we demonstrated that viral genotypes 
fluctuate while patient is on the Tenofovir therapy, 
revealing two important phenomena, first, there is 
mixture of viral populations present in HBV infected 
patient and secondly, at a given time, only one of the 
viral strain is inhibited/exhibits[36]. Although, not with 
regard to the HBV genotypes, but from the point of HBV 
quasispecies an elegant study by Buti et al[37] identified 
HBV quasi-species evolution after LT in patients under 
long-term lamivudine prophylaxis with or without HBIG 
and there was low transient viremia detected even in 
the absence of serum HBsAg, showing importance of 
continuing HBV prophylaxis. In the same context, a 
recent case study by Mina et al[38] showed that HBV 
genotypes fluctuates after LT, which could possibly be 
the main reason behind the HBV reactivation in liver 
transplant settings. Since, in diagnostic assays, the 
possible source of HBV reactivation is negated, it is an 
open question, if extrahepatic tissues should be tested 
to find the origin of such reactivation. Studies focusing 
on HBV recurrence based on genotype are summarized 
in Table 1. It would be worthwhile to consider HBV 
genotyping in both donor and recipient so that each 
viral strain is tracked in case of the mixed genotype 
infections, which are emerging as important hidden 
source for reactivation.
Co-existing hepatitis D virus infection and HBV 
reactivation 
Hepatitis delta virus (HDV) consists of a single-stranded 
RNA molecule enveloped by hepatitis B surface antigen 
(HBsAg)[39]. One of the risk factors of HBV recurrence 
in LT patients is the co-infection with hepatitis delta 
virus (HDV)[40]. Fulminant hepatitis B reactivation in 
co-infected patients has been reported[40,41]. HBsAg-
positive liver grafts in HBsAg-positive recipients 
with HDV co-infection has been reported to result in 
virological recurrence and rapid development of liver 
cirrhosis, and need for re-transplant[42,43]. HDV is a RNA 
pathogenic virus that requires presence of HBV for its 
survival[44]. Studies on post-LT patients suggest that the 
absence of HBV prophylaxis or lack of proper function 
of HBIG leads to higher incidence of both HBV and HDV 
reinfection[43,45,46]. 
The co-existence or co-infection of HBV and HDV 
is very commonly observed, obviously due to the 
dependence of HDV infection on HBV. For instance, 
11.9% of HBV-positive patients were also positive for 
HDV in an Italian liver patient cohort, with a higher 
incident in patients older than 50 years[47]. It also 
appears to have a geographical connection, as co-
infection HBV-HDV in LT patients was found to be low 
in Japan[48], possibly due to the differential geographical 
distribution of HDV genotypes Ⅰ and Ⅱ between other 
parts of the world and Asian countries, respectively[49]. 
The helper functions of HBV provide the support to HDV 
for cell entry, replication, virion assembly and export[50]. 
The interactions between HBV-HDV occur in two phases, 
the first phase of active HDV replication occurs with the 
suppression of HBV, followed by reactivation of HBV and 
reduction in HDV in the second phase[51]. Due to this 
nature of HDV and HBV interactions, early recurrence of 
HDV has been detected in many patients in the absence 
of HBV recurrence[52]. Studies also imply that HDV 
could be a cause for many subclinical infections and 
symptoms develop rapidly upon recurrence of HBV[45]. 
HBV recurrence has been shown to cause atypical 
reappearance of HBV infection and HDV relapse in the 
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allographs[53]. Additionally, the recurrence of HBV-HDV 
post-LT is the cause of death for many LT patients, 
prompting need for more research on this subject[45,54]. 
In a recent study, recurrence rate of HBV after LT was 
not different from the recurrence rate of HBV-HDV co-
infection on long-term low-dose HBIG prophylaxis along 
with TDF[55].
Genetic variations of host genetic makeup in predicting 
HBV reactivation 
Genetic variations of host genetic makeup may play 
some role in increased/reduced risk of HBV reactivation 
after LT. Single-nucleotide polymorphisms (SNP) of two-
gene locus cytotoxic T lymphocyte antigen-4 (CTLA-4) 
+49 and CD86 +1057 were previously reported to 
influence the outcome of LT with respect to allograft 
acceptance[56,57]. Homozygosity for CTLA-4 +49 (G/G 
genotype) was reported to be associated with reduced 
risk of HBV recurrence in post-LT Chinese patients[56]. 
CD86 and CTLA-4 are known to stimulate and inhibit T 
cell activation, respectively. 
Role of superinfection in HBV reactivation 
Superinfection is defined as the infection with a second 
virus or a different strain of virus at a later time point, 
after the establishment of persistent infection of the first 
virus[51,58]. 
Superinfection with HDV of an individual chro-
nically infected with HBV may have deleterious 
consequences[59]. This pattern of infection causes a 
severe acute hepatitis that may be self-limited but that in 
most cases (up to 80%) progresses to chronicity[60]. The 
resultant chronic HDV infection usually exacerbates the 
preexisting CHB[60]. It is to be noted that HBV replication 
is usually suppressed by HDV, and this suppression 
becomes persistent in the case of a chronic HDV 
infection[61,62]. Due to concern for HDV superinfection 
in post-LT setting, it is of utmost importance to 
prevent HBV recurrence after LT. Nonetheless, patients 
chronically co-infected with HDV are less at risk of HBV 
recurrence and have a better survival rate than patients 
infected with HBV alone. Patients co-infected with 
HDV generally do not require pre-transplant antiviral 
therapy due to HBV suppression and low viral load. 
Although potent HBV DNA-polymerase inhibitors can 
control HBV replication, reappearance of HBsAg and/or 
the persistence of HBV DNA in serum, liver, or PBMC 
might have deleterious consequences in the setting of 
HBV-HDV co-infection as they may provide the biologic 
substrate to the reactivation of HDV[40]. No effective 
antiviral drug is available for the treatment of graft 
infection with HDV, and potentially the best approach 
is to keep them on long-term potent antiviral therapy 
along with low dose of HBIG (Figure 1).
As mentioned before, HBV has ten genotypes 
named A-J, and they influence the disease outcome 
and treatment to antiviral therapy[63]. Depending on 
the geographical location, patients may have one 
or mixed genotypes of HBV in infected patients and 
consequences of which possibly have the recombinant 
HBV genotypes[64-66]. The genotype C of HBV was 
observed in majority of the HBV-infected patients with 
acute exacerbation[67]. An earlier published review 
reported that HBV genotypes D and C are associated 
with a lower rate of favorable response to alfa-interferon 
and pegylated-interferon alfa-2b therapy than genotypes 
A and B[68]. The rate of resistance to lamivudine (LAM) 
was higher in patients with genotype A infection than in 
patients infected by genotype D, whereas no difference 
in the risk of LAM resistance is found between patients 
HBV genotype No. of patients Median follow-up (mo) HBV recurrence number (%) Mortality number (%)
Girlanda et al[175], 2004
   A 15   56   4 (27)   2 (13)
   D 13   67   7 (54)   5 (38)
   A/D 12   43   4 (33)   2 (17)
   A/C   2   66   1 (50) 0
   E   2   45   1 (50)   1 (50)
   C   1 106     1 (100) 0
Devarbhavi et al[34], 2002
   A 10   56   3 (30)   1 (10)
   C   6     22.5   3 (50)    1 (10)
   D   5   15   3 (60)    1 (10)
   E   1     1 0 Lost follow-up
Gaglio et al[176], 2008
   A 28   24      3 (10.7)      3 (10.7)
   B   8   24      1 (12.5)      1 (12.5)
   C 18   24    1 (5.5)    5 (5.5)
   D   6   24 0 0
Lo et al[177], 2005
   B 43   36 4 (2)    7 (17)
   C 74   36 21 (15) 7.5 (11)
HBV: Hepatitis B virus.
Table 1  Recurrence of hepatitis B virus in different genotypes
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with genotype B and patients with genotype C[68]. Later 
studies using potent nucleotide analogue have shown no 
genotype specific differences in treatment responses[69]. 
Another challenge with HBV is the generation of HBV 
variants through splicing. These variants may get 
activated with the disease progression post-LT leading to 
undesirable clinical outcomes as well as the development 
of drug resistance[70]. 
Role of HBV integration in HBV reactivation after LT
The role of HBV DNA integration in the genome of host 
liver cells has been studied from the early 1980s and it 
had long been postulated to have implications for the 
antiviral therapy for HBV[71,72]. Recent study demon-
strated that HBV can integrate into the host genome 
immediately after its invasion[73]. HBV DNA integration 
has been detected in all the stages of HBV infection 
including occult HBV infection[74]. The potential for onco-
genicity has been proven in the woodchuck model with 
occult WHV infection[75]. In a study from Japan, eighty-
two consecutive Japanese patients with cirrhosis, who 
were negative for serum HBsAg and antibody to hepa-
titis C virus (anti-HCV) were observed for a median of 
5.8 years[76]. The HCC development rates in the patients 
HBV DNA-positive and HBV DNA-negative were 27.0% 
and 11.8% at the end of the 5th year, and 100% and 
17.6% at the 10th year, respectively.
The clinical significance of occult HBV infection has 
not been well studied in LT recipients. A recent study 
investigated the prevalence of occult HBV infection in 
cirrhotic patients undergoing LT in a Brazilian referral 
center[77]. Liver samples from 68 adults were analyzed 
using a nested polymerase chain reaction assay for HBV 
DNA and occult HBV infection was diagnosed in three 
(4.4%) patients. Markers of previous HBV infection 
were available in two patients with occult HBV infection 
and were negative in both. Clinical impact of occult HBV 
infection in immunosuppressed individuals has been 
recently reviewed[78]. These results suggest potential 
for HBV reactivation post-LT from occult HBV infection. 
In fact, a recent study with 43 patients with alcoholic 
cirrhosis, who were negative for serum HBsAg before LT, 
detectable HBV DNA in the explanted liver was evident 
in 41.9%[79]. De novo HBV infection occurred in 18.6% 
(8/43) of the recipients at a median of 10 mo after LT.
Extrahepatic replication of HBV and its role in HBV 
reactivation
Numerous reports demonstrated the presence of HBV 
DNA, virus genome replicative intermediates and viral 
proteins in hepatic tissue, and HBV DNA and HBsAg 
in serum of HBV-infected persons, but the existence 
of extrahepatic sites of HBV replication are not as 
well recognized. Nonetheless, the accumulated data 
indicate that PBMC and different immune cell types can 
support HBV replication[27,80-83]. Stronger evidence came 
from the woodchuck model of HBV infection[27,75,84-87]. 
There are also occasional observations that endothelial 
cells, epithelial cells, neurons, macrophages and 
polymorphonuclear leukocytes could be permissive to 
anti-HBc(+) liver grafts
HBsAg(+) recipient
anti-HBc(+)
and/or
anti-HBs(+) recipient
HBsAg(-)
and
anti-HBs(-) recipient
(hepatitis B naive patient)
anti-HBc(+)
anti-HBs(+)
anti-HBc(+)
anti-HBs(-)
anti-HBc(-)
anti-HBs(+)
HBIG and 
nucleoside analog
No prophylaxis
Nucleoside analogs
Nucleoside analogs
Nucleoside analogs
No
No
Yes
Yes
Figure 1  Stepwise approach of anti-hepatitis B core positive grafts allocated to recipients based on their hepatitis B serology. In chronic hepatitis B patients 
with HBsAg positive and who receive Anti-HBc positive liver grafts should be treated with HBIG and nucleoside analogs. If the recipient is HBsAg negative and Anti-
HBc positive and/or anti HBs positive, NA is used for prophylaxis based on anti HBc and anti HBs serologies. No prophylaxis is recommended for anti-HBc positive 
and anti-HBs positive liver in LT recipient without HBsAg positive serology. These patients should be followed with periodic HBV DNA level guided by ALT to monitor 
for any relapse.  In Hepatitis B naïve patients, NA is recommended for prophylaxis. HBIG: Hepatitis B Immunoglobulin; HBsAg: Hepatitis B surface antigen; Anti-HBs: 
Hepatitis B surface antibody; Anti-HBc: Hepatitis B core antibody.
Chauhan R et al . HBV reactivation after liver transplantation
357 March 27, 2018|Volume 10|Issue 3|WJH|www.wjgnet.com
HBV infection in humans[88]. HBV replication was also 
demonstrated in in vitro bone marrow cultures and 
lymphatic tissues of patients with CHB[89-91]. In the 
woodchuck model of hepatitis B, extrahepatic replication 
of the woodchuck hepatitis virus and infectivity of 
the virus derived from lymphoid cells were clearly 
delineated[75,87]. Interestingly, in some situations, the 
lymphatic (immune) system might be the only site of 
virus replication in this model[75,86,87,92]. 
In one of the xenotransplantation study in patients 
with baboon liver transplants, Lanford et al[93] 
demonstrated the persistence of HBV DNA in several 
extrahepatic tissues after HBV replication halted in the 
liver. In the woodchuck model, the mothers with resident 
hepadnaviral infection cells transmit the infection to 
their offspring which is predominantly restricted to their 
lymphatic system[84]. These observations suggest that 
the attachment preferences of HBV to cellular receptors 
on diverse cell types might be responsible for the 
quasispecies specific compartmentalization of HBV[94]. 
Studies related to genetic variability, drug resistance 
and potential immune evasion mechanisms of virus 
in plasma and PBMC of patients with CHB have also 
been investigated[95,96]. Because of the diverse nature 
of the HBV in hepatic and extrahepatic tissues, the 
response to therapy has been shown to be different in 
PBMC-restricted HBV compared to hepatic HBV[95]. In 
these studies, liver, plasma as well as PBMC samples 
were evaluated using ultrasensitive assays for the 
quasispecies compatibility in LT patients under long 
term prophylaxis. The authors inferred that extrahepatic 
HBV is always detectable in the serum, liver, and PBMC 
of almost all patients despite prophylaxis, supporting 
continuation of anti-HBV therapy[95,96]. However, there is 
not a study yet that demonstrated that reactivation can 
solely originate from extrahepatic sites.
THE RISK OF HBV REACTIVATION IN LIVER 
TRANSPLANT PATIENTS UNDERGOING 
IMMUNOSUPPRESSION THERAPY
Upon HBV entry, the level at which HBV persists 
depends on the interplay between the viral replication 
rate and the host immune response. LT patients with 
prior HBV infection could experience a reactivation of 
HBV following LT due to immunosuppressive therapy, 
potentially leading to deleterious consequences, 
including graft failure and death[97-99].
HBV reactivation in immunosuppressed patients 
Immune mechanism: HBV cccDNA and low levels 
of HBV DNA and RNA remain detectable in host 
hepatocytes even in patients exposed to HBV who 
have developed anti-HBs after apparent complete 
clearance of serum HBsAg and HBV DNA from a 
recent infection[87,100]. Hence, there seems to be 
a balance between host HBV-specific T cell and 
innate immune responses and virus replication that 
maintains the latency of the viral infection[80,101,102]. 
Immunosuppressive therapy or cancer chemotherapy 
may lead to induce imbalance of these mechanisms 
which causes HBV reactivation[101,103].
Non-immune mechanism: HBV infection can also 
be flared by steroids[104]. This may include stimulation 
of a glucocorticoid-responsive element (GRE) in the 
HBV genome which leads to up regulation of HBV 
gene expression[105]. In addition, mechanistic target 
of rapamycin (mTOR) inhibitors, like rapamycin, that 
are used as immunosuppressive drugs in LT patients 
and certain cancers, are reported to enhance HBV 
reactivation in patients[106]. It is also shown that 
maintaining an immunosuppressive regimen using 
mTOR-inhibitors post-LT commonly reactivate HBV 
infection, along with infections with other viruses, 
such as HCV, cytomegalovirus (CMV), HIV-1, human 
papilloma virus (HPV), Epstein Barr virus (EBV) and 
herpes simplex virus (HSV) as well[107].
HCC recurrence after LT 
In a Chinese registry study, patients undergoing 
LT due to HBV-related HCC vs HCV-related HCC 
demonstrated recurrence of HCC at a significantly 
higher rate in HBV-HCC cohort (26.39%) compared to 
that in HCV-HCC cohort (9.07%) (P < 0.001)[108]. The 
risk factors for HCC recurrence were: elevated serum 
alpha fetoprotein, large tumor volume, microvascular 
invasion, high serum HBV DNA and HBsAg levels, and 
immunosuppression[109,110]. 
Younger age has been suggested as a significant 
risk factor for HBV infection-related HCC recurrence 
after LT. It has been proposed that this could be due 
to the vertical transmission of HBV from the occult 
HBV infection harboring mother and HBV immune 
tolerant state of the younger patients, triggering HCC 
recurrence[111,112].
PROPHYLAXIS FOR HBV REACTIVATION 
AFTER LT
HBsAg-positive patients 
Introduction of HBIG in prevention of HBV reactivation 
following LT was a major milestone. HBIG is pooled 
polyclonal antibody against HBsAg. Although its 
mechanism of action remains incompletely understood, 
it is believed that it prohibits binding of virions to 
hepatocytes or promotes lysis of infected hepatocytes[113]. 
In the initial days, prophylaxis for recurrent HBV infection 
was administered to HBsAg-positive patients using HBIG 
or LAM monotherapy. This strategy showed significant 
reduction in re-infection and improvement of graft 
survival after LT[14,15,114]. Although graft survival was 
largely improved with either HBIG or LAM monotherapy, 
the re-infection rates were continued to be 30%-40% 
of patients[15,19,115]. Furthermore, LAM monotherapy 
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resulted in development of HBV reverse transcriptase 
mutations that lead to antiviral drug resistance. When 
LT patients were on only HBIG prophylactic therapy, 
their chance of developing HBV escape mutations was 
significantly higher[116], and this lead to de novo HBV 
infection in some patients after LT[17,117]. First described 
in 1998, combination therapies of HBIG with NA were 
successful in controlling HBV infection in most of the 
patients. None of the 59 patients undergoing LT for HBV-
related liver failure who received high dose of HBIG 
intra- and post-operatively in combination with LAM 
as prophylaxis, showed detectable HBV DNA after 459 
days of treatment[118]. By combining LAM with HBIG, 
the HBV recurrence rate further dropped to less than 
5%. The success of this combination regimen led it to 
become the most favored antiviral prophylactic regimen 
in lLT centers worldwide. Despite being effective, HBIG 
was very expensive and unavailable to a significant 
percentage of the patient population, and it requires 
regular parental injections and monitoring. In view of 
this, lower-dose HBIG in combination with LAM was 
evaluated and was found to be equally effective[119-121]. 
However, this combination approach of HBIG with 
an oral antiviral medication is of historical value only 
and neither alone was sufficient in preventing HBV 
reactivation or recurrence. With the availability of newer 
and more potent oral NA, there has been a shift from 
HBIG combination therapy to NA alone. A systematic 
review by Cholongitas et al[122] noted a higher recurrence 
rate with combination of HBIG plus LAM compared to 
HBIG plus ETV/TDF (6.1% vs 1%, P = 0.004). A meta-
analysis has shown that compared to high dose HBIG-
LAM combination, low dose HBIG and potent NAs 
(TDF or ETV) demonstrated significantly lesser HBV 
recurrence[123]. Both ETV and TDF have been associated 
with resistance rate of less than 2% after 5 years in 
patients with HBV infection[124]. Several earlier studies 
have demonstrated usefulness of long term HBIG, and 
more recent studies have demonstrated safe withdrawal 
of HBIG with continuation of oral antiviral therapies 
alone by adopting a limited duration of HBIG use in the 
protocol[119,121,125-138] (Tables 2 and 3).
Hepatitis B core antibody-positive liver donor
LT from hepatitis B core antibody (anti-HBc)-positive 
donors is being increasingly used due to the shortage 
of organs. However, due to immunosuppressive 
therapy, the risk of HBV reactivation is higher after 
LT in these patients[139]. In a systematic review of 39 
studies involving 903 LT patients, Cholongitas et al[139] 
evaluated the risk of HBV recurrence after LT with 
grafts from anti-HBc-positive donors and effect of anti-
HBV prophylaxis. HBV recurrence was found to be 
11% in HBsAg-positive LT patients who received anti-
HBc-positive grafts compared to anti-HBc-negative 
grafts, but overall survival was same in both groups. 
They also noted that de novo HBV infection occurred 
in 19% of HBsAg-negative patients receiving anti-HBc-
positive grafts. Without prophylaxis, HBV re-activation 
was 15% in anti-HBc/anti-HBs-positive recipients and 
48% in HBV naïve patients. However, prophylaxis using 
HBIG, LAM or a combination decreased re-infection rate 
significantly. Similarly, de novo HBV infection rates in 
HBsAg-negative patients decreased to 19%, 2.6% and 
2.8% using HBIG, LAM and combination, respectively. 
This study suggests that anti-HBc positive grafts 
can be donated safely to HBsAg-positive and anti-HBc/
anti-HBs-positive sub groups, and antiviral prophylaxis 
decreases post-LT reactivation significantly. Due to 
high risk of reactivation in HBV-naïve patients, anti-
HBc-positive grafts should only be considered if other 
two sub-group recipients are not available[140]. Figure 2 
shows stepwise approach in allocating anti-HBc-positive 
grafts based on recipients HBV serology and prophylaxis 
after LT. 
Anti-HBs and Anti- HBc-positive recipients
De novo HBV infection is substantially lower in anti-
HBc and/or anti-HBs-positive compared to HBV-naive 
recipients[141]. The presence of anti-HBs seems to 
protect from de novo HBV infection and both anti-HBc 
and anti-HBs-positive recipients represent a group that 
can safely receive anti-HBc-positive liver grafts without 
any post-transplant HBV prophylaxis (probability of 
de novo HBV infection < 2%)[142-151]. These patients 
should however be followed with periodic HBV DNA 
level guided by ALT to monitor for any relapse. Despite 
this low risk, many centers prefer to continue with NA 
without HBIG in this subgroup of patients, and future 
studies will further clarify this concept (author’s personal 
communication). Figure 3 shows stepwise approach in 
allocating anti-HBc-positive grafts based on recipients 
HBV serology and prophylaxis after LT. 
Duration of HBIG administration
Currently, there is no consensus regarding the duration 
of use and dose of HBIG as a component of prophylaxis, 
and many experts believe in an individualized approach 
to use of HBIG in prophylaxis[152-154]. A recent study has 
demonstrated that in HBV-infected patients undergoing 
LT, who have HBV DNA levels less than 100 U/L and 
an absence of co-infection with HIV or HDV, a very 
short course of HBIG in combination with long-term 
antiviral therapy is highly effective in preventing HBV 
recurrence[130]. Chen et al[131] has shown infusion of 
two high doses of HBIG during surgery in combination 
with ETV significantly prevented HBV recurrence and 
improved the 3-year survival after LY. Another, potential 
cost saving approach could be combination of ETV plus 
low-dose on-demand HBIG[155]. Additionally, HBIG-free 
approach has recently been advocated and is discussed 
in the later part of this review. 
HBIG-free prophylaxis and treatment options
Advent of newer and more-potent NAs with high 
genetic barrier for resistance such as ETV and TDF, 
have shown great therapeutic potential as prophylactic 
agents, and achieved a stronger viral suppression, 
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Ref. NA HBIG protocol Median follow-up 
(mo)
HBV recurrence
Angus et al[119], 2000 32 LAM 400 IU or 800 IU/d for 1 wk from  
LT followed by 400 IU or 800 IU/
monthly thereafter
   18.4 3.1% HBsAg + and 0% HBV DNA+
Gane et al[121], 2007 147 LAM 400 IU or 800 IU/d for 1 wk followed 
by 400 IU or 800 IU/monthly 
thereafter
62 1% at 1 yr and 4% at 5 yr. Baseline 
HBV DNA was associated with 
HBV recurrence
Karademir et al[125], 2006 33 LAM, 
2 LAM + ADV
All patients received 4000 IU 
of intramuscular HBIG during 
surgery, 2000 IU intramuscular daily 
thereafter, until the HBsAb titer 
> 200 IU/mL and the HBsAg was 
seronegative, followed by lifelong 
1200 to 2000 IU HBIG on-demand if 
HBsAb titer fell below 100 IU/mL
16 5.7% (2 of 35 patients) had HBV 
DNA recurrence.
They were LAM resistant
Iacob et al[126], 2008 42 LAM 10000 IU within anhepatic phase and 
daily within the first postoperative 
week, followed by 2500 IU on 
demand
   21.6 HBV recurrence rate was 4.8% after 
a median of 1.8 yr
Jiang et al[127], 2010 254 LAM 2000 IU in anhepatic phase, followed 
by 800 IU/d for first day then weekly 
for the rest of 3 wk in the first post-
operative month, then  800 IU 
monthly
   41.2 1-, 3- and 5-yr HBV recurrence 
rates were 2.3%, 6.2% and 8.2%, 
respectively 5 cases have YVDD 
mutations
Nath et al[128] , 2006 14 LAM + ADV 1000 IU HBIG in anhepatic phase 
1000 IU/daily for week 1, then HBIG 
withdrawn, replaced with oral ADV
   14.1 7.1%
Saab et al[129], 2011 18 LAM + HBIG, 
16 LAM to LAM + ADV
Randomized trial 
Patients treated with low dose HBIG 
+ LAM ≥ 1-yr post LT
18 patients continued HBIG
16 patients discontinued HBIG and 
ADV added
21 0% in HBIG + LMV
6.1% in LMV + ADV
Recurrent case: HBsAg + /HBV 
DNA (-)
Saab et al[129] , 2011 19 LAM to LAM + ADV, 
41 LAM to LAM + TDF, 
1 ETV to ETV + ADV
All patients treated with low dose 
HBIG + LAM ≥ 1-yr post-LT.
All patients discontinued HBIG
15 3.3% recurrent cases: HBsAg (+)/
HBV DNA (-)
Radhakrishnan et al[130], 2017 42 (ETV (12%), TDF (83%), or 
TDF/FTC (5%) 
HBIG 5000 IU given in anhepatic 
phase and daily for 5 d together with 
nucleos(t)ide  analogues   after LT 
and then continued indefinitely.
36 1- and 3-year cumulative 
incidences of recurrence, defined 
by positive serum HBsAg of 2.9%
Chen et al[131], 2015 50 (ETV before and after LT) Two doses of HBIG-First dose 
anhepatic phase (10000 IU) and 
other dose (10000 IU) during surgery 
(additional doses as needed to 
maintain HBIG level > 300 IU/mL 
from 6 wk to 12 mo)
36 0% recurrence at 3 years defined as 
reappearance of HBsAg and HBV 
DNA level
Cholangitas et al[132], 2016 34 (LAM = 2, AFV = 1, ETV = 
9, TDF = 12)
HBIG 1000-10000 IU bolus during 
anhepatic phase, followed by daily × 
7 d, and then monthly  1000-2000 IU 
intramuscularly for 6-12 mo post-LT 
and then discontinued 
NA were continued indefinitely 
28 5.8% recurrence defined as 
reappearance of serum HDV in LT 
recipients with detectable serum 
HBsAg and/or HBV DNA
Wesdorp et al[133], 2013 17 (15 of 17 converted from  
LAM/ADV  to TDF/FTC)
All received HBIG ± (10000 IU given 
during anhepatic phase followed 
by a 4-7 d course of 10000 IU of 
IV HBIG daily, and then monthly 
intramuscularly for > 6 mo and then 
switched to TDF/FTC 
24 No recurrence defined by HBsAg 
and HBV-DNA  positivity. 
However, 6.7% had isolated 
HBsAg recurrence
Stravitz et al[134], 2012 21 (Patients were initially on 
LAM = 11, ETV = 4, AFV = 
2, LAM + ADV = 2, LAM + 
ADV = 2. All patients were 
converted to TDF/FTC)
HBIG ± nucleos(t)ide  > 6 mo, then 
substituted with TDF/FTC
31 0% recurrence of HBV DNA after  
switching to TDF/FTC 
Taperman et al[135], 2013 37 patients were randomized 
to TDF/FTC plus HBIG (n 
= 19) or receive (TDF/FTC) 
alone (n = 18)
HBIG ± nucleos(t)ide for 24 wk, then 
randomized to TDF/FTC plus HBIG 
(n = 19) or receive TDF/FTC alone (n 
= 18) for an additional 72 wk
72 0% recurrence of HBV DNA in 
both arms
Table 2  The results of combination therapy of low-dose hepatitis B immunoglobulin and nucleos(t)ide analogues and the effects of 
withdrawal of hepatitis B immunoglobulin from combination therapy
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paving the way for a HBIG free regimen for antiviral 
prophylaxis[13,156]. In a multicenter trial by Gane et al[136], 
no HBV recurrence was detected in 28 HBV patients who 
received a combination of LAM and ADV after a median 
follow-up of 22 mo when the pre-transplant HBV-DNA 
level was below 3 log(10) IU/mL. In a later study of 
75 HBV patients who received different oral antiviral 
treatment after LT (19 received a combination of LAM 
and ADV, 42 ETV, 12 TDF, and 2 received a combination 
of ETV and TDF), the HBV recurrence rate was merely 
8% at a median follow-up of 21 mo and there was 
no mortality related to HBV recurrence[157]. There was 
no significant difference in HBsAg clearance and HBV-
DNA suppression between those on LAM, combination 
treatment, or ETV, but virological relapse rate at 3 years 
was 17%, 7%, and 0%, respectively (P < 0.001).
Fung et al[158] evaluated monotherapy with NAs 
(LAM, ETV or LAM plus ADV) without HBIG in a large, 
long-term cohort study involving 362 LT patients 
with CHB. At the end of 8 years of follow-up, 98% 
showed undetectable HBV DNA in serum by clinical 
assay. Overall 8-year survival rate was 83% with no 
difference between these three treatment groups 
and, importantly, no mortality was observed due to 
HBV recurrence in any of the 362 patients. This study 
showed that at least in low risk patients, HBIG-free 
regimen with high potency NAs was safe and effective 
in preventing post-LT HBV reactivation. For patients 
without preexisting LAM-resistant mutation, the use 
of ETV as a standalone treatment remains an ideal 
choice given its lack of nephrotoxicity. In a study of 
80 CHB patients undergoing LT where ETV was used 
alone in a completely HBIG-free regimen with a median 
follow-up of 26 mo a high HBsAg seroclearance rate 
of 86 and 91% after 1 and 2 years respectively was 
observed[159]. Thirteen percent of patients had HBsAg 
positivity either from reappearance of HBsAg after initial 
seroclearance or from persistence of HBsAg-positive 
status after transplantation. It is important to note 
that there was no incidence of virological rebound or 
Gane et al[136], 2013 20 patients with initial HBIG 
for 7 d and then switched to 
LAM+ ADV
HBIG 800 intramuscularly given 
immediately after LT and the daily 
for 7 d  and then switched to LAM/
ADV
57 0% recurrence defined as 
reappearance of HBsAg and HBV 
DNA
McGonigal et al[137,141], 2013 4 (ETV = 2, LAM = 1, TDF = 1) HBIG + NA for more than one year 
and switched to TDF/FTC
15 0% recurrence of HBsAg and HBV 
DNA
Angus et al[138], 2008 34 patients randomized after 
12 mo of HBIG +LAM to ADV 
(n = 16) with and without 
HIBIG (n = 18)
Low dose HBIG × 12 mo along with 
LAM
4.4 yr for the 
LAM/ADV and 
4.6 yr for the 
HBIG/LAM 
group
1 of 15 (6%) in the LAM/ADV and 
0 of 15 (0%) in the HBIG/LAM 
group had HBsAg positive at last 
follow up
HBIG: Hepatitis B immunoglobulin; HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; HCC: Hepatocellular carcinoma; HIV: Human 
immunodeficiency virus; HDV: Hepatitis delta virus; LAM: Lamivudine; LT: Liver transplantation; ETV: Entecavir; TDF: Tenofovir.
Ref. No. of 
patients
Median duration 
of follow-up (mo)
Therapy HBsAg loss Undetectable HBV DNA
Fung et al[161], 2017 265 59 ETV At 1, 3, 5, and 8 yr of 
follow up, 85%, 88%, 
87.0%, and 92% were 
negative for HBsAg, 
respectively
At 1, 3, 5 and 8 yr of follow up, 95%, 99%, 
100%, and 100% had undetectable HBV 
DNA, respectively
Fung et al[158], 2013 362 53 LAM = 176 (49%), ETV = 142 
(39%), and 44 (12%) were 
on combination therapy 
(Either LAM or ETV) plus 
nucleotide analog (either 
ADV or TDF)
HBsAg seronegativity  at 
1, 3, 5 and 8 yr was 80%, 
82%, 82% and 88%
HBV DNA suppression to undetectable 
levels at 1, 3, 5 and 8 yr was 94%, 96%, 
96%, and 98%. Rate of HBV DNA 
suppression for LAM, combination 
therapy, and ETV at 1 yr was 97%, 94%, 
and 95%, respectively
Fung et al[159], 2011   80 26 ETV The cumulative rate of 
HBsAg loss was 86% 
and 91% after 1 and 2 yr, 
respectively
95% with undetectable HBV DNA and 5% 
had low level viremia 
Wadhawan et al[157], 2013   75 21 19 patients received a 
combination of LAM+ADV, 
42 received entecavir, 12 
received TDF, and 2 received 
a combination of ETV + TDF
The cumulative 
probabilities of clearing 
HBsAg were 90% 
and 92% at 1 and 2 yr 
after transplantation, 
respectively
Nine patients were HBsAg-positive with 
undetectable DNA at the last follow-up. 
The recurrence rate in our series was 8% 
(6/75)
HBV: Hepatitis B virus; HBsAg: Hepatitis B surface antigen; LAM: Lamivudine; ETV: Entecavir; TDF: Tenofovir.
Table 3  Hepatitis B immunoglobulin-free regimens in preventing recurrence of hepatitis B virus infection after liver transplantation
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resistance, nor any HBV-related graft hepatitis, graft 
loss, or mortality. The same group later also followed 
histological outcomes of CHB patients treated with an 
HBIG-free regimen, 42 patients were treated with ETV 
monotherapy who underwent liver biopsies after LT at a 
median time of 10 mo. Of these, 9 were serum HBsAg-
positive at the time of biopsy. All patients were serum 
HBV DNA-negative- at the time of biopsy. None of these 
patients had histological evidence of HBV-related graft 
hepatitis and positive immunohistochemical staining 
for HBsAg[160]. Fung et al[161] also shown the long-term 
efficacy of using ETV monotherapy in a study involving 
165 LT recipients with HBV. The study demonstrated 
that ETV monotherapy is highly effective at preventing 
HBV reactivation after LT for CHB, with a durable HBsAg 
seroclearance rate of 92%, an undetectable HBV DNA 
rate of 100% at 8 years, and excellent long-term 
survival of 85% at 9 years.
This approach has been supported by another 
recent study by Cholngitas et al[132]. They have shown 
that maintenance therapy with NAs prophylaxis after 
HBIG discontinuation was effective against HBV/HDV 
recurrence, but it seems that a longer period of HBIG 
administration might be needed before it is withdrawn 
after LT. Another large study from Asia has shown 
long-term ETV monotherapy (without HBIG) is highly 
effective at preventing HBV reactivation after LT for 
CHB, with a durable HBsAg seroclearance rate of 92%, 
an undetectable HBV DNA rate of 100% at 8 years, and 
excellent long-term survival of 85% at 9 years. The 
positive outcomes with the use of ETV monotherapy 
without HBIG has challenged the need for HBIG post-
LT[161] A recent network metanalysis has shown that 
ETV resulted with the highest probability (31%) as the 
best prophylactic option on reducing the risk of HBV 
recurrence. ETV is the preferred oral NAs treatment 
compared to other five different prophylactic regimens 
(LAM, TDF, ADV, LAM plus ADV, LAM plus TDF) in the 
prevention of HBV recurrence after LT[162]. With currently 
preferred antivirals, namely, those with high barrier 
to resistance, more patients are likely to have low or 
undetectable viral load at the time of transplantation 
and an HBIG-free regimen will more likely be acceptable 
in the vast majority (Figures 2 and 4). On the other 
hand, HBIG is still an integral part of prophylaxis in 
high-risk patients with high pre-transplant HBV DNA 
level, presence of HCC at LT, co-infection with HIV and 
HDV, presence of drug-resistance and non-compliance 
with therapy[152]. However, duration of HBIG in such 
patients can be guided by testing of serial serum HBV 
DNA level, and HBsAg status (Figures 2 and 4). A recent 
study however has challenged this notion, and noted 
that oral antiviral therapy alone without HBIG is highly 
effective in preventing reactivation of HBV infection and 
graft loss from recurrent hepatitis B after LT in patients 
with preexisting HBV LAM resistance[163]. The cumulative 
rate of HBsAg seroclearance at 1, 5, and 10 years 
was 82%, 88%, and 91%, respectively. At the time 
Virus
dose
Site of 
infection
Serological pattern 
of infection
Infection/disease 
outcome
Final 
outcome
Post-LT risk factors for 
HBV reactivation
Lymphatic system
Low dose
< 103 virions
High dose
> 103 virions
Serologically 
silent1
Serologically 
silent2
Serologically 
silent3
Primary occult 
infection
Secondary occult 
infection
Resolved acute 
hepatitis
Chronic hepatitis
Serologically 
silent life-long 
persistence
Serologically 
evident life-long 
persistence
Immunosuppression
Drug resistant HBV
HCC at LT
High HBV DNA at LT
HDV or HIV co-infection
Non-adherence to therapy
Figure 2  Generalized concept of overt and occult hepatitis B virus infections based on the data from the woodchuck model of hepatitis B, their long-
term outcomes, and associated risk factors for hepatitis B virus reactivation following liver transplant. Based on experimental infection in the woodchuck 
model (Mulrooney-Cousins PM, Michalak TI, 2015[92]). 1Serologically silent infection: HBsAg, anti-HBc and anti-HBs negative; HBV DNA positive; 2Serologically silent 
infection: HBsAg negative, anti-HBc positive, anti-HBs positive or negative; HBV DNA positive; 3Serologically evident infection: HBsAg and anti-HBc positive, anti-HBs 
negative. HBV DNA positive. SOI: Secondary occult infection; POI: Primary occult infection; LT: Liver transplant; HCC: Hepatocellular carcinoma; HBV: Hepatitis B 
virus; HDV: Hepatitis D virus; HBsAg: HBV surface antigen; anti-HBc: Antibodies to HBV core antigen; anti-HBs: Antibodies to HBV surface antigen.
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of transplantation, 39 (72%) patients had detectable 
HBV DNA, with a median of 4.5 log copies/mL. The 
cumulative rate of HBV undetectability was 91% at 1 
year, increasing to 100% by 5 years. After 1 year of LT, 
over 90% of the patients had undetectable HBV DNA, 
and from 8 years onward, 100% had undetectable HBV 
DNA in serum. The long-term outcome was excellent, 
with survival of 87% at 12 years after transplantation, 
without any mortality related to HBV reactivation. 
However, HBIG does provide additional benefits beyond 
preventing HBV recurrence in LT recipients such as its 
association with reduced rates of rejection[164,165], and 
modifying risk of developing HCC post-LT[166]. Another 
important consideration is the potential for preventing 
graft reinfection such that subsequent discontinuation 
of all immunoprophylaxis can be considered[167]. The 
proposed algorithm for HBV prophylaxis for CHB 
patients undergoing LT is summarized in Figures 1 and 3.
Complete discontinuation of all prophylaxis
Based on the previous data and clinical studies, lifelong 
prophylaxis is currently advocated to LT patients to 
prevent HBV recurrence. Lenci et al[167] investigated 
the safety of withdrawal of prophylactic measures in 
selected LT patients using a stepwise protocol. The 
LT patients underwent liver biopsies after receiving 
a HBIG-LAM combination therapy. It was shown 
that careful withdrawal of HBIG was safe in patients 
with undetectable HBV viremia at transplantation 
and no evidence of total and intrahepatic cccDNA. 
Chronic HBV infection 
(HBsAg positive)
Entecavir (if no prior LAM)
or
Tenofovir (renally adjusted dose)
Check HBV DNA level 
at liver transplant
HBV DNA
undetectable
HBV DNA
detectable
Entecavir
or 
Tenofovir
Without HBIG indefinitely
HBV DNA
< 2000 IU/mL
HBV DNA
≥ 2000 IU/mL
Assess risk of recurrence
Negative Risk factors Positive
Entecavir
or
Tenofovir
Without HBIG indefinitely
Drug resistant HBV 
HIV co-infection
HDV co-infection
HCC at LT
High dose HBIG 10000 IU IV in 
the anhepatic phase followed 
by low dose HBIG 600-1000 
IU IM daily × 7 d and weekly 
× 3 wk, then monthly (target 
= anti-HBs > 100 IU/mL) 
and entecavir or tenofovir 
indenfinitely
Check HBV DNA by PCR and 
HBsAg before HBIG monthly 
and discontinue HBIG once HBV 
DNA and HBsAg is undetectale
Figure 3  Proposed algorithm for hepatitis B prophylaxis in liver transplant patients. In chronic hepatitis B patients Entecavir (if no prior Lamivudine therapy) 
or Tenofovir (adjusted to renal function) is recommended as the first line therapy. Based on HBV DNA level at the time of transplant and risk factors, HIBG should be 
initiated, if associated risk factors for HBV recurrence post LT. High risk patients include drug resistant HBV, HIV co-infection, HDV co-infection, HCC. This group of 
patients receive high dose IV HBIG 10000 IU given during the anhepatic phase followed by low dose HBIG to achieve target anti HBs > 100 IU/mL along with NAs. 
HBIG is discontinued once HBV DNA is undetectable and loss of HBsAg is achieved. HBIG: Hepatitis B immunoglobulin; HBV: Hepatitis B virus; HBsAg: Hepatitis B 
surface antigen; HCC: Hepatocellular carcinoma; HIV: Human immunodeficiency virus; HDV: Hepatitis delta virus; LAM: Lamivudine; LT: Liver transplantation.
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More recent study showed that complete prophylaxis 
withdrawal is safe in patients transplanted for HBV-
related disease at low risk of recurrence and is often 
followed by spontaneous anti-HBs seroconversion[168]. 
However, based on previous studies many centers 
continue prophylaxis indefinitely as low level HBV 
viremia is known to persist even after many years 
of therapy[167,169], and complete discontinuation of all 
preventative therapy cannot be recommended at this 
time and should only be performed in the setting of a 
clinical trial[170]. 
HBV vaccination and active immunity
Although there is no effective clearance, to ensure 
a maximum suppression of HBV in LT patients and 
avoidance of escape mutations caused by long-term 
administration of HBIG or NAs, it is crucial to develop a 
strong and long lasting immune response against HBV. 
Several trials have noted an increase in anti-HBs titer 
in up to 65% of patients who received HBV vaccination 
after LT following HBIG withdrawal[141]. More recent 
study looking at active immunization in de novo HBV 
infection after LT with a HBV core antigen-positive graft 
have shown that active immunization is effective in 
preventing de novo infection if the post-transplant anti-
HBs level is maintained above 100 IU/L with vaccination 
and antiviral prophylaxis. Prophylaxis can be safely 
discontinued in this group of patients who obtain this 
immunity[171].
Emerging therapies and the future of HBV treatment
Current HBV prophylaxis and treatment modalities 
can only suppress but do not eradicate HBV infection 
completely; therefore there is a lifelong need for the 
therapy. Recently, there is a renewed interest to target 
various stages HBV replication cycle and its interaction 
with the host. 
DAAs and host-targeting agents (HTA) are the two 
major categories that are being developed and are 
at various phases of clinical trials[2,13]. Among these, 
DAAs act by inhibiting viral enzymatic activities or 
protein function, and generally have excellent safely 
profile, therefore present an attractive option for drug 
manufacturers. Major HBV target-specific classes of 
DAAs that are being developed are inhibitors of cccDNA 
(e.g., CRISPR/Cas9, sirt1/2, MC2792), hepatocyte entry 
receptor inhibitors (via NTCP; i.e., mycludex, ezetimibe), 
HBV DNA polymerase inhibitors (HB pol; e.g., GS-7340, 
besifovir), siRNA target (ARC-520/521), core allosteric 
modulators (CpAM; e.g., NVR 3-778), immune 
modulators (e.g., GS9620, nivolumab, pidilizumab), 
and therapeutic vaccines (e.g., TG-1050)[2,172-177]. These 
drugs are at various stages of clinical trials and they 
indicate a promising future for HBV prophylaxis and 
treatment. 
CONCLUSION
With the advent of LT is currently regarded as the 
ultimate option for treatment for liver cirrhosis, liver 
failure and HCC associated with chronic HBV infection. 
Phenomenal success in allograft survival has been 
achieved by use of HBIG and oral antiviral medications. 
Prophylaxis with low dose HBIG and oral anti-HBV 
nucleotides is universally accepted as an effective option 
to reduce post-transplant viral reactivation. Availability 
of newer oral anti-HBV nucleos(t)ide analogs (NA), 
such as ETV and TDF, with higher barriers to resistance 
and better knowledge of risk factors associated with 
post-LT HBV reactivation have allowed incorporating 
these newer NA as part of the antiviral regimen after 
LT for CHB patients. The use of combination HBIG and 
lamivudine remains only of historical interest at this 
time as neither alone was sufficient to prevent HBV 
recurrence. ETV with its excellent safety profile, low 
nephrotoxicity, remains the agent of choice for patients 
without prior lamivudine resistance. For those with 
prior resistance, the addition of TDF is likely the best 
treatment option. LT with anti-HBc-positive donors is 
now possible due to better understanding of the balance 
between recurrence risk and availability of individualized 
prophylaxis strategies, and has expanded the pool of 
donor in an era with high demand for cadaveric donor 
with scarce supply. Current treatment regimen for 
A B
Figure 4  Immunostaining. A: Recurrent hepatitis B virus infection leading to cirrhosis in a post-liver transplantation patient. Figure shows cirrhotic nodules with 
cholestasis but no appreciable inflammation; B: Immunostaining for hepatitis B core antigen shows strong nuclear accumulation of antigen in a small proportion of 
hepatocytes indicating active virus propagation.
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HBV can only control HBV replication, but cannot fully 
eradicate. As such, efficacy of HBV prophylaxis should 
be measured by its ability to prevent graft hepatitis and 
loss secondary to HBV infection, and not in terms of 
achieving a cure. With currently available potent NA we 
can achieve substantial suppression of HBV replication, 
but we are far from achieving viral eradication, 
although newer antiviral treatments approaches are 
in development. Hence, a positive HBsAg in post-LT 
period does not necessarily means HBV recurrence, as 
the patient has never achieved a virological cure. It is 
for the same reason we can argue that continuation 
of HBIG to achieve seroclearance of HBsAg does not 
achieve any clinical utility as long as viral suppression 
is achieved with NA. By administering HBIG to keep 
the antibody titers above a certain arbitrary level, 
serum HBsAg logically becomes undetectable because 
of the formation of immune complexes, which evades 
detection. However, this does not equate to complete 
eradication, nor the reappearance of serum HBsAg upon 
stopping HBIG signifies reactivation. In fact, hepatitis B 
core antigen remains detectable in the liver throughout 
HBIG administration despite serum HBsAg negativity. 
As such, long-term prophylaxis with HBIG does not 
serve any clinical utility and early discontinuation of this 
practice should be considered as long as complete viral 
suppression is achieved. 
Emerging therapies are now focusing on newer 
targets of HBV replication and virus-host interaction 
with an ambitious goal of eradicating HBV infection in 
the near future rather than mere viral suppression. 
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